Candel Therapeutics, Inc. (CADL): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Candel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 cadl-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“ Agreement ”) is made between Candel Therapeutics, Inc., a Delaware corporation (the “ Company ”), and Charles Schoch. (the “ Executive ”) and is made effective as of June 12,
How this was made
The 30-second read
Why it matters
The disclosure updates officer compensation structure (base salary, target bonus eligibility) and specifies equity acceleration upon a change in control plus involuntary termination or voluntary termination for good reason.
Market read
This is a governance/compensation update that may marginally affect sentiment but does not include new financial results, guidance, or strategic transaction details.
What to watch
Traders may focus on the CFO appointment/terms, but the more market-relevant signal would be any concurrent operational update (financing, trial readouts, or strategic review) which is not present here.
Background
The 8-K reports Item 5.02, including an employment agreement for CFO Charles Schoch effective June 12, 2026.
Ticker impact
Candel Therapeutics disclosed a new CFO employment agreement with a $468,600 base salary and change-in-control equity acceleration terms.
Likely limited immediate price impact; any move would be small and sentiment-driven.
The filing is an 8-K employment agreement detail (comp/benefits and equity acceleration) without disclosed financial guidance, operational milestones, or litigation outcomes.
Market effects
Minimal—this is company-specific executive compensation and does not signal sector-wide regulatory or clinical changes.
Minimal—no geographic or macro linkage beyond general small-cap sentiment.
Minimal—no international deal, trial, or regulatory action disclosed.
Counterpoint
The change-in-control acceleration and termination provisions could be interpreted as positioning for a potential transaction, but the filing provides no explicit deal or timeline.
Key entities
- companyCandel Therapeutics, Inc.
Issuer filing the 8-K and entering the CFO employment agreement.
- executiveCharles Schoch
Named executive in the employment agreement as Chief Financial Officer.
